Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

161. MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1 (PubMed)

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1 The five-year survival rate of non-small cell lung cancer (NSCLC) patients is very low. MiR-873 is involved in the growth, metastasis, and differentiation of tumors. Herein, we determined the target gene and influence of miR-873 in NSCLC.MiRanda and Targetscan websites were used to predict the target gene of miR-873 in NSCLC. Luciferase activity (...) . These results indicate that miR-873-GLI1 signaling is involved in gefitinib resistance in NSCLC.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

162. BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer (PubMed)

BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer 30234143 2018 11 14 2331-4737 5 7-8 2018 Jul Oncoscience Oncoscience BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer. 218-219 10.18632/oncoscience.455 Lochmann Timothy L TL Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Bouck Ynes M YM Anthony Faber: Philips Institute for Oral (...) Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. Faber Anthony C AC Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA. eng Journal Article 2018 08 14 United States Oncoscience 101636666 2331-4737 BCL-2 apoptosis SCLC targeted therapy CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 06 13 2018 06 19

Full Text available with Trip Pro

2018 Oncoscience

163. MiR‐520b restrains cell growth by targeting HDAC4 in lung cancer (PubMed)

MiR‐520b restrains cell growth by targeting HDAC4 in lung cancer MicroRNAs (miRNAs) function as tumor promoting or tumor suppressing factors in many cancers. MiR-520b contributes to progression in head-neck and liver cancers, spinal osteosarcoma, and glioma; however, the association of miR-520b with lung cancer progression remains unknown. In this investigation, we explore the effect of miR-520b targeting HDAC4 on lung cancer growth.The regulation of miR-520b or its inhibitor on HDAC4 (...) decrease in HDAC4 expression was observed in lung cancer A549 cells treated with different doses of miR-520b. The miR-520b inhibitor enhanced HDAC4 expression in lung cancer cells. Bioinformatics predicted the targeting of miR-520b on HDAC4. MiR-520b directly targeted the 3' untranslated region of HDAC4. The introduction of miR-520b obviously inhibited cell proliferation in vitro. Anti-miR-520b was capable of accelerating lung cancer cell proliferation; however, HDAC4 knockdown destroyed anti-miR-520b

Full Text available with Trip Pro

2018 Thoracic cancer

164. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy (PubMed)

Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy While there is growing interest in the correlation between chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer, very few studies have examined the interaction between COPD and small cell lung cancer (SCLC). Therefore, the aim of this study was to examine the impact of COPD on the survival of patients with SCLC.The medical records (...) = 0.581), whereas the median PFS rates were 6.65 and 6.57 months, respectively (log-rank test, P = 0.559). Multivariate analysis identified Eastern Cooperative Oncology Group performance status ≥ 2 and extensive-stage SCLC as independent risk factors for shorter OS; however, coexisting COPD was not a predictor of survival.Although over half of the SCLC patients receiving chemotherapy had COPD, coexisting COPD had no impact on the survival of patients with SCLC.© 2018 The Authors. Thoracic Cancer

Full Text available with Trip Pro

2018 Thoracic cancer

165. Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? (PubMed)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? 30116594 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? e000421 10.1136/esmoopen-2018-000421 Pirker Robert R Department of Medicine I, Medical University of Vienna, Vienna, Austria. eng Editorial 2018 08 10 England ESMO Open 101690685 2059-7029 (...) PD-l1 biomarker immunotherapy predictive factor prognosis Competing interests: RB received honoraria from Merck Sharp Dohme for serving as a member of the Data Monitoring Committee of pembrolizumab trials in lung cancer. 2018 07 16 2018 07 17 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116594 10.1136/esmoopen-2018-000421 esmoopen-2018-000421 PMC6088342 N Engl J Med. 2015 Oct 22;373(17):1627-39 26412456 N Engl J Med. 2018 Jun 14;378(24):2288-2301 29863955 J Thorac Oncol. 2017 Feb;12(2

Full Text available with Trip Pro

2018 ESMO open

166. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. (PubMed)

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Broad-based genomic sequencing is being used more frequently for patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the association between broad-based genomic sequencing and treatment selection or survival among patients with advanced NSCLC in a community oncology setting.To compare clinical outcomes (...) ]; P = .40) vs unmatched cohort (hazard ratio, 0.69 [95% CI, 0.62 to 0.77]; log-rank P < .001).Among patients with advanced non-small cell lung cancer receiving care in the community oncology setting, broad-based genomic sequencing directly informed treatment in a minority of patients and was not independently associated with better survival.

Full Text available with Trip Pro

2018 JAMA

167. Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis (PubMed)

Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis This study was conducted to investigate the value of the T cell spot test for tuberculosis (T-SPOT.TB) for the diagnosis of patients with lung cancer combined with pulmonary tuberculosis (LCTB).Thirty-six patients diagnosed with LCTB who received treatment at Shandong Provincial Chest Hospital from September 2014 to 2017 were randomly chosen and enrolled (...) clinical application.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

168. Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? (PubMed)

Surgically treated lung cancer patients: do they all smoke and would they all have been detected with lung cancer screening? Since publication of the National Lung Cancer Screening Trial (NLST) results early lung cancer detection has been widely studied, targeting individuals based on smoking history and age. However, over recent decades several changes in lung cancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among (...) lung cancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria. All patients operated on for lung cancer in a university hospital in Estonia between 2009 and 2015 were included. Data were collected from hospital records. 426 patients were operated on for lung cancer, with smoking history properly documented in 327 patients (87 females; median age 67 years). 170 (52%) patients were smokers, 97 (30

Full Text available with Trip Pro

2018 ERJ open research

169. Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study (PubMed)

Correlation between radiomic features based on contrast‐enhanced computed tomography images and Ki‐67 proliferation index in lung cancer: A preliminary study The purpose of the study was to investigate the association between radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lung cancer.One hundred and ten patients with lung cancer confirmed by surgical histology were retrospectively included. Radiomic (...) features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features serving as image predictors of Ki-67 status in lung cancer and to investigate the relationship between these features and Ki-67 PI.Higher Ki-67 expression was more common in men (P = 0.02) and patients with a smoking history (P = 0.01). Twelve radiomic features were

Full Text available with Trip Pro

2018 Thoracic cancer

170. Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial

Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial Incorporating tobacco treatment within lung cancer screening programs has the potential to influence cessation in high-risk smokers. We aimed to better understand the characteristics of smokers within a screening cohort, correlate those variables with downstream outcomes, and identify predictors of continued smoking.This study is a secondary analysis (...) of the National Lung Screening Trial randomized clinical study. Tobacco dependence was evaluated by using the Fagerstrӧm Test for Nicotine Dependence, the Heaviness of Smoking Index, and time to first cigarette (TTFC); descriptive statistics were performed. Clinical outcomes (smoking cessation, lung cancer, and mortality) were assessed with descriptive statistics and χ2 tests stratified according to nicotine dependence. Logistic and Cox regression models were used to study the influence of dependence

2018 EvidenceUpdates

171. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib (...) that favored crizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longest OS was observed in crizotinib-treated patients who received a subsequent ALK tyrosine kinase inhibitor. No new safety signals were identified. Conclusion The final analysis of the PROFILE 1014 study provides a new benchmark for OS in patients with ALK-rearranged non-small-cell lung cancer and highlights the benefit of crizotinib for prolonging survival in this patient population.

2018 EvidenceUpdates

172. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced

2018 EvidenceUpdates

173. Incorporating Coexisting Chronic Illness into Lung Cancer Screening: A Research Statement

Incorporating Coexisting Chronic Illness into Lung Cancer Screening: A Research Statement AMERICANTHORACICSOCIETY DOCUMENTS IncorporatingCoexisting ChronicIllness into Decisionsabout Patient Selection for LungCancer Screening An Of?cial American Thoracic Society Research Statement M. Patricia Rivera, Nichole T. Tanner, Gerard A. Silvestri, Frank C. Detterbeck, Martin C. Tammem¨ agi, Robert P. Young, Christopher G. Slatore, Tanner J. Caverly, Cynthia M. Boyd, Dejana Braithwaite, Joelle T. Fathi (...) -makingwithpatientswhomaynot bene?tfromLCSowingtocoexistingchronicillness.Thisstatement establishesaresearchframeworktoaddressessentialquestions regarding how toincorporateand communicaterisks of comorbiditiesintopatientselectionanddecisionsregardingLCS. Keywords: lung cancer screening; comorbidities; communication of risk Contents Overview Key Conclusions and Recommendations Introduction Methods Results Juxtaposing Lung Cancer Risk and Competing Risk of Death from Other Causes COPD, Lung Cancer Risk, Competing Risk

2018 American Thoracic Society

174. Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) 1 alectinib 150mg hard capsules (Alecensa ® ) SMC2012 Roche Products Limited 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process alectinib (Alecensa ® ) is accepted for use within NHS Scotland. Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC. This SMC advice takes account of the benefits

2018 Scottish Medicines Consortium

175. Lung cancer

Lung cancer Top results for lung cancer - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lung cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

176. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer P Pembrolizumab for untreated PD- embrolizumab for untreated PD- L1-positiv L1-positive metastatic non-small-cell e metastatic non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

177. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer Alectinib for untreated ALK Alectinib for untreated ALK-positiv -positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer T echnology appraisal guidance Published: 8 August 2018 nice.org.uk/guidance/ta536 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

178. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer (PubMed)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second-line topotecan chemotherapy.We retrospectively evaluated the records of SCLC patients treated in our department from January 2007 to December 2016 who received second-line topotecan chemotherapy (...)  = 0.005).TOPO1 expression was prevalent in SCLC patients. Strong expression was associated with an elevated disease control rate after second-line topotecan chemotherapy. Patients with sensitive disease that relapsed after first-line chemotherapy had better survival than refractory patients who received second-line topotecan chemotherapy.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

179. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution (PubMed)

Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Purpose Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non-small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated (...) Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival

Full Text available with Trip Pro

2018 Journal of global oncology

180. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer (PubMed)

Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early‐stage non‐small cell lung cancer S100A13 plays a key role in tumor growth and metastasis. The purpose of this study was to investigate the prognostic significance of S100A13 expression, microvessel density (MVD), and survival in early stage non-small cell lung cancer (NSCLC).In silico analysis was performed to determine the associations between S100A13 and NSCLC. The data of 82 (...) was significantly higher in tumors with high (67.6%, 25/37) compared to low S100A13 expression (13.3%, 6/45) (P < 0.01).High S100A13 expression is closely associated with high intratumoral angiogenesis and poor prognosis in patients with stage I NSCLC. Immunohistochemical evaluation of S100A13 expression, along with an examination of the perioperative extent of angiolymphatic invasion, has value for predicting prognosis.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley

Full Text available with Trip Pro

2018 Thoracic cancer